Curtis Lockshin, Ph.d.
Vice President for Healthcare Outcomes Policy and
Oncology and Molecular Radiation Sciences
World Gastroenterology Organisation
Norway
Biography
Dr. Lockshin comes to RXi providing exceptional industry insight and functional, hands-on experience. He currently serves as the CEO of Guardum Pharmaceuticals, LLC in Lexington, MA, a wholly owned US subsidiary of OJSC Pharmsynthez which is headquartered in St. Petersburg, Russia. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO’s R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical Research
Research Interest
Foundation, a Duke University Support Corporation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor’s new leads initiative. He is a Co-Inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.
